Item 1A. Risk Factors
ITEM 1A. RISK FACTORS
You should carefully consider the key risks
described below together with all of the other information included in this report and our Annual Report on Form 10-K, filed with the
Securities and Exchange Commission on April 26, 2023, before making an investment decision with regard to our securities. The risks set
forth below and in our Form 10-K are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely
affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results
of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant
part of your investment.
Because we are an early-stage company with
minimal revenue and a history of losses and we expect to continue to incur losses for the foreseeable future, we cannot assure you that
we can or will be able to operate profitably.
We did not generate any revenue prior to the quarter
ended October 31, 2018 and, since then, we have reported only modest revenue from our pharmaceutical transdermal patch business. We are
subject to the risks common to start-up, pre-revenue enterprises, including, among other factors, undercapitalization, cash shortages,
limitations with respect to personnel, financial and other resources and lack of revenues. Drug development companies typically incur
substantial losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug
has received FDA approval, which cannot be assured, and until the company has started to sell the product. We can give no assurance that
we can or will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early
stage of operations. We cannot assure you that we will be able to operate profitably or generate positive cash flow. If we cannot achieve
profitability, we may be forced to cease operations and you may suffer a total loss of your investment.
Because we do not have a product we can
market in the United States, we cannot predict when or whether we will operate profitably.
We have not completed the development of our lead
product, which is our abuse deterrent fentanyl transdermal system, and we do not have any product that we can market in the United States.
Because of the numerous risks and uncertainties associated with product development, we cannot assure you that we will be able to develop
and market any products or achieve or attain profitability. If we are able to obtain financing for our operations, we expect that we will
incur substantial expenses as we continue with our product development and clinical trials. Further, if we are required by applicable
regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which we may seek to market
product, to perform studies in addition to those we currently anticipate, our expenses will increase beyond expectations and the timing
of any potential product approval may be delayed. As a result, we expect to continue to incur substantial losses and negative cash flow
for the foreseeable future.
A number of factors, including, but not limited
to the following, may affect our ability to develop our business and operate profitably:
●
our ability to obtain necessary funding to develop our proposed products;
●
the success of clinical trials for our products;
24
●
our ability to obtain FDA approval for us to market any proposed product in our pipeline in the United States;
●
any delays in regulatory review and approval of product in development;
●
if we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing and distribution agreements with qualified third parties;
●
market acceptance of our products;
●
our ability to establish an effective sales and marketing infrastructure;
●
our ability to protect our intellectual property;
●
competition from existing products or new products that may emerge;
●
the ability to commercialize our products;
●
potential product liability claims and adverse events;
●
our ability to adequately support future growth; and
●
our ability to attract and retain key personnel to manage our business effectively.
Our business is impacted by the following additional
key risks :
●
Our business could be adversely affected by the effects of health pandemics or epidemics, including the recent outbreak of COVID-19, which was declared by the World Health Organization as a global pandemic, and is resulting in travel and other restrictions to reduce the spread of the disease, including state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. The effects of these orders, government-imposed quarantines and measures we would take, such as work-from-home policies, may negatively impact productivity, disrupt our business and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.
●
The FDA regulatory process may take longer and be more expensive than we anticipate without any assurance that we will obtain FDA approval.
●
If we are not able to obtain FDA approval for our lead product, we may not have the resources to develop any other product, and we may not be able to continue in business.
●
We may not be able to launch any products for which we receive FDA marketing approval.
●
We may not be able to establish a distribution network for the marketing and sale of any products for which we receive FDA approval.
●
We may not be able to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility.
●
It may be necessary to us to enter into a joint venture or other strategic relationship in order to develop, perform clinical testing for, manufacture or market any of our proposed products. We may not be able to enter into such a relationship, and any relationship may not be successful, and the other party may have business interests and priorities that are different from ours.
●
We are party to a settlement agreement with the SEC resulting from statements in our SEC filings that did not accurately reflect the FDA’s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United States. The settlement included a cease-and-desist order against violating the provisions of the Securities Exchange Act which require us to file accurate registration statements and annual reports with the SEC. Our failure to comply with our obligations under the settlement agreement could result in enforcement proceedings against us or our officers.
25
●
We may not be able to protect our rights in our intellectual property, and we may be subject to intellectual property litigation which would be expensive and disruptive of our operations even if we eventually prevail on the merits.
●
Unanticipated side effects or other adverse events resulting from the use of our product could require a recall of our products and, even if no recall is required, our reputation could be impaired by side effects.
●
We may not be able to evaluate potential acquisition candidates, with the result that we may not be able to benefit from the acquisition or integrate the acquired business with our business. We have recently incurred an impairment charge as a result of an acquisition when the intellectual property assets of the acquired company were not as represented. We cannot assure you that we will not incur similar or other problems with any future acquisitions.
●
We may fail to comply with all applicable laws and regulations relating to our product. We may have to change or adapt our operations in the event of changes in national, regional and local government regulations, taxation, controls and political and economic developments that affect our products and the market for our products;
●
We may be unable to accurately estimate anticipated expenses, capital requirements and needs for additional financing;
ITEM 6. EXHIBITS.
Exhibit
Number
Description of Exhibits
31.1
Section 302 Certificate of Chief Executive Officer.
31.2
Section 302 Certification of Chief Financial Officer
32.1
Section 906 Certificate of Chief Executive Officer and Principal Financial Officer.
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
26
SIGNATURES
In accordance with the requirements of the Exchange
Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NUTRIBAND INC.
June 9, 2023
By:
/s/ Gareth Sheridan
Gareth Sheridan,
Chief Executive Officer
(Principal Executive Officer)
June 9, 2023
By:
/s/ Gerald Goodman
Gerald Goodman,
Chief Financial Officer
(Principal Financial and Accounting Officer)
27
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.